A Phase IV, Randomized, Observer-Blind, Multi-Center, Non Inferiority Comparison of the Immune Response of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Inactivated Split-Virion Influenza Vaccine in Adults Aged Greater Than or Equal to 65 Years.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 29 Nov 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Influenza virus vaccine (Afluria) (Primary) ; Influenza virus vaccine
Indications Influenza virus infections
Focus Pharmacodynamics
Sponsors CSL; Seqirus

Most Recent Events

11 Sep 2009 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
11 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov
02 Oct 2008 Actual start date (Oct 2009) added as reported by Clinicaltrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight